On October 26, 2022 Papyrus Therapeutics Inc reported that Data will be presented by R Yang and colleagues from the Guangxi Medical University Cancer Hospital and H Gabra demonstrating that intravenously administered rOPCML-Fc has excellent tumor targeting affinity forhuman ovarian cancer patient derived xenografts (PDX) and produces strong dose dependent monotherapy efficacy both in-vitro and in-vivo (Press release, Papyrus Therapeutics, OCT 26, 2022, View Source;utm_medium=rss&utm_campaign=papyrus-therapeutics-research-presentation-at-the-34th-eortc-nci-aacr-meeting-in-barcelona-spain-on-27th-october%25ef%25bf%25bc [SID1234623197]). Intravenous treatment at 10mg/kg over 4 weeks showed a 93% reduction in tumor volume without any obvious toxicities as judged by lack of differences in animals’ activities and weight in treated animals, as compared with control vehicle treated animals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Scientific Officer Professor Hani Gabra commented "We are excited to present these data which confirm that our approach to the intravenous restoration of tumor suppression function is indeed feasible, efficacious and safe using our recombinant engineered Fc fusion Opioid Binding/Cell Adhesion Molecule-like [rOPCML]. These encouraging results are consistent with data generated by Papyrus and support the company’s effort to develop novel extracellular tumor suppressor therapies."